Skip to main content
SpringerLink
Log in

Recent Advances in Drug Delivery Via Pressured Metered-Dose Inhalers

  • Conference paper
Optimization of Aerosol Drug Delivery

Abstract

Riker Laboratories launched the first commercial pressurised metered-dose inhalers (pMDIs), containing isoprotenerol and epinephrine, in 1956. To this day, it remains the most commonly prescribed device for inhaled asthma medications, with world-wide production exceeding 500 million devices (Tansey, 1997a). The size of these canisters will vary, but assuming that they contain on average 120 doses, this equates to 2000 doses of medication taken every second !

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agu RU, MI Ugwoke, M Armand, R Kinget and N Verbeke. “The lung as a route for systemic delivery of therapeutic proteins and peptides.” Respiratory Research (2001) 2: 198–209.

    Article  PubMed  CAS  Google Scholar 

  • Ayres JG, AB Millar and AP Sykes. “Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurised metered dose inhaler to patients with severe asthma.” Respiratory Medicine (2000) 94 (Supplement B): s42–s50.

    Google Scholar 

  • Bowman PA and D Greenleaf. “Non-CFC metered dose inhalers: the patent landscape.” International Journal of Pharmaceutics (1999) 186: 91–94.

    Article  PubMed  CAS  Google Scholar 

  • Brambilla G, D Ganderton, R Garzia, D Lewis, B Meakin, P Ventura. “Modulation of aerosol clouds produced by pressurised inhalation aerosols.” International Journal of Pharmaceutics (1999) 186: 53–61.

    Article  PubMed  CAS  Google Scholar 

  • Britto IL. “Metered dose inhaler for fluticasone propionate.” United States Patent No. US6253762 (2001)

    Google Scholar 

  • Brown AR and JA Pickrell. “Propellant-driven aerosols for delivery of proteins in the respiratory tract.” Journal of Aerosol Medicine (1995) 8:43–58.

    Article  PubMed  CAS  Google Scholar 

  • Brutsche MH, IC Brutsche, M Munawar, SJ Langley, CM Masterson, PT Daley-Yates, R Brown and A Woodcock. “Pharmacokinetics and systemic effects of fluticasone propionate are different in asthmatics and normal volunteers”. Lancet 356 (August 2000):556–561.

    Article  PubMed  CAS  Google Scholar 

  • Burt PCW and LKH Kwok. “Method and apparatus for introducing into a container a suspension or solution of a material in a propellant held under pressure.” European Patent No. 0419261 (1993)

    Google Scholar 

  • Busse WW, S Brazinsky, K Jacobson, W Strieker, K Schmitt, J Vanden Burgt, D Donnell, S Hannon and GL Colice. “Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant.” Journal of Allergy and Clinical Immunology 104 (1999): 1215–1222.

    Article  PubMed  CAS  Google Scholar 

  • Clark A. “The physics of aerosol formation by MDIs — limitations of the current approach.” Journal of Biopharmaceutical Sciences (1992) 3: 69–76.

    CAS  Google Scholar 

  • Commission to the Council and the European Parliament. “Strategy for the phase-out of CFCs in metered-dose inhalers. Official Journal of the European Communities (1998) COM 603.

    Google Scholar 

  • Committee for Proprietary Medicinal Products. “Results of the co-ordinated review of 1, 1, 1, 2- tetrafluroethane HFC-134a.” European Commission, Brussels 1994.

    Google Scholar 

  • Committee for Proprietary Medicinal Products. “Results of the co-ordinated review of 1, 1, 1, 2, 3, 3, 3- heptafluropropane (HFC-227).” CPMP/503/95 .European Agency for the Evaluation of Medicinal Products, London 1995.

    Google Scholar 

  • Craig-McFeely PM, JB Soriano, WC Maier, J Riley and SAW Shakir. “Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England: Final results.” American Journal of Respiratory and Critical Care Medicine (2001) 163: a857.

    Google Scholar 

  • Custovic A, SCO Taggart, A Stuart, A Robinson and A Woodcock. “Efficacy of a new non-ozone depleting formulation for salbutamol.” Journal of Pharmaceutical Medicine 5 (1995): 161–168.

    Google Scholar 

  • Derendorf H, G Hochhaus, B Meibohm, H Mollmann and J Barth. “Pharmacokinetics and pharmacodynamics of inhaled corticosteroids.” Journal of Allergy and Clinincal Immunology 101 (SupplS)(1998):S440–S446.

    Article  Google Scholar 

  • Derendorf H. PT Daley-Yates, LN Pierre, J Efthimiou. “Bioavailability and metabolism of mometasone furoate: Pharmacology versus methodology.” Journal of Clinical Pharmacology. (2002) 42: 383 – 387.

    PubMed  CAS  Google Scholar 

  • Dershwitz M, JL Walsh, RJ Morishige, PM Conners, RM Rubsamen, SL Shafer and CE Rosow. “Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers.” Anesthesiology. (2000) 93:619–628.

    Article  PubMed  CAS  Google Scholar 

  • Farman JC, BG Gardiner and JD Shanklin. “Large losses of total ozone over Antarctica reveal serious ClOx/Nox interaction.” Nature (325): 207–210.

    Google Scholar 

  • Gabrio BJ, SW Stein and DJ Velasquez. “A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers.” International Journal of Pharmaceutics (1999) 186: 3–12.

    Article  PubMed  CAS  Google Scholar 

  • Harrison LI, I Soria, J Machacek et al. “Pharmacokinetic profile of improved lung delivery with CFC-free ultrafine aerosol steroid inhaler [Abstract]”. Am JRespir Crit Care Med (1997) 155: A666.

    Google Scholar 

  • Harrison LI, I Soria, AC Cline and BP Ekholm. “Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics.” Journal of Pharmacy and Pharmacology. (1999) 51: 1235–1240.

    Article  PubMed  CAS  Google Scholar 

  • Hirst PH, GR Pitcairn, JG Weers, TE Tarara, AR Clark, LA Dellamary, G Hall, J Shorr J and SP Newman. “In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler.” Pharmaceutical Research (2002) 19:258–264.

    Article  PubMed  CAS  Google Scholar 

  • Howlett D and J Colwell. “Improvements in extractables from pMDI elastomer systems.” Pp 36–38 in Drug Delivery to the Lungs VIII Portishead, UK: The Aerosol Society, 1997.

    Google Scholar 

  • International Pharmaceutical Aerosols Consortium. “World-wide availability on CFC-free MDIs”. www.ipacmdi.com (2001)

    Google Scholar 

  • Julius SM, JM Sherman and L Hendeles. “Accuracy of three electronic monitors for metered-dose inhalers.” Chest (2002) 121: 871–876.

    Article  PubMed  Google Scholar 

  • Leach CL. “Improved delivery of inhaled steroids to the large and small airways.” Respiratory Medicine 92(SupplA)(1998):3–8.

    Article  PubMed  Google Scholar 

  • Leach, CL, PJ Davidson and RJ Boudreau. “Improved airway targeting with CFC-free HFA- beclomethasone metered-dose inhaler compared with CFC-beclomethasone.” European Respiratory Journal. (1998) 12: 1346–1353.

    Article  PubMed  CAS  Google Scholar 

  • Lundback B, R Dahl, M De Jonghe, N Hyldebrandt, R Valta and SL Payne. “A comparison of fluticasone propionate when delivered by either the metered-dose inhaler or the Diskhaler inhaler in the treatment of mild-to-moderate asthma.” European Journal of Clinical Research 5 (1994): 11–19.

    Google Scholar 

  • McDonald KJ and GP Martin. “Transition to CFC-metered dose inhalers — into the new millennium.” International Journal of Pharmaceutics (2000) 201:89–107.

    Article  PubMed  CAS  Google Scholar 

  • Molina MJ and FS Rowlands. “Stratospheric sink for chlorofluoromethane: chlorine atom catalysed destruction of ozone.” Nature (1974): 810–812.

    Google Scholar 

  • Peart J, JC Orban, P McGlynn, MP Redmon, CM Sargeant and PR Byron “MDI electrostatics: valve and formulation interactions that really make a difference.” Pp 223–230 in Respiratory Drug Delivery VIII: Raleigh, NC, Davis Horwood International, 2002.

    Google Scholar 

  • Pedersen S. “Do inhaled corticosteroids inhibit growth in children?” American Journal of Respiratory & Critical Care Medicine. (2001) 164: 521–535.

    Article  CAS  Google Scholar 

  • Polli GP, WM Grim, FA Bacher and MH Yunker. “Influence of formulation on aerosol particle size.” Journal of Pharmaceutical Sciences (1969) 58:484–486.

    Article  PubMed  CAS  Google Scholar 

  • Quinn EA, RT Forbes, AC Williams, MJ Oliver, L McKenzie and TS Purewal. “Protein conformational stability in the hydrofluoroalkane propellants tetrafluoroethane and heptafluoropropane analysed by Fourier transform Raman spectroscopy.” International Journal of Pharmaceutics (1999) 186:31–41.

    Article  PubMed  CAS  Google Scholar 

  • Sharma S, D White, AR Imondi, ME Placke, DM Vail and MG Kris. “Development of inhalational agents for oncologic use.” Journal of Clinical Oncology (2001) 19:1839–1847.

    PubMed  CAS  Google Scholar 

  • Smith IJ. “The challenge of reformulation.” Journal of Aerosol Medicine (1995) 8 (Supplement): S19- S27.

    Article  Google Scholar 

  • Stefely JS, D Duan, P Myrdal, D Ross, DW Schultz and CL Leach “Design and utility of a novel class of biocompatible excipients for HFA-based MDIs.” Pp 82–90 in Respiratory Drug Delivery VIL Raleigh, NC, Serentec Press 2000.]

    Google Scholar 

  • Summers M. “Control and regulation of HFA pMDIs”. Pp 119–22 in Respiratory Drug Delivery VI: Buffalo, II, Interpharm Press 1998.

    Google Scholar 

  • Taggart SCO, A Custovic, DH Richards, AA Woodcock. “GR106642X: A new, non-ozone depleting propellant for inhalers.” British Medical Journal 310 (1995): 1639–1640.

    Article  PubMed  CAS  Google Scholar 

  • Tansey I. “Changing to CFC-free inhalers: the technical and clinical challenges.” Pharmaceutical Journal (1997)259:896–898.

    Google Scholar 

  • Tansey I “The technical transtion to CFC free inhalers.” British Journal of Clinical Practice (1997) 89 (Suppl): 22–27.

    PubMed  CAS  Google Scholar 

  • The Management Forum “The CFC crisis and portable therapy.” Reported in Manufacturing Chemist (July 1992): 22–23.

    Google Scholar 

  • Terzano C. “Pressurized metered dose inhalers and add-on devices.” Pulmonary Pharmacology and Therapeutics (2001) 14: 351–366.

    Article  PubMed  CAS  Google Scholar 

  • Tiwari D, D Goldman, S Dixit, WA Malick and PL Madan. “Compatibility evaluation of metered dose inhalers with tetrafluoroethane (PI34a), a non-CFC propellant.” Drug Development and Industrial Pharmacy (1998) 24:345–352.

    Article  PubMed  CAS  Google Scholar 

  • Tonnel AB, J Bons, M Legendre, A Prud’Homme, B Bugnas, I Evano-Celli and AM Stuart. “Clinical efficacy and safety of fluticasone propionate 250 Dg twice daily administered via a HFA 134a pressurised metered dose inhaler to patients with mild to moderate asthma.” Respiratory Medicine (2000) 94 (Supplement B): s29–s34.

    Google Scholar 

  • United Nations. “Kyoto Protocol to the United Nations Framework Convention on Climate Change”. UNEP/INC/98/2. Geneva: Information Unit for Conventions, UNEP (1998).

    Google Scholar 

  • Warby RJ “Improvements in drug delivery devices” European Patent Application No. 1208864 (2002).

    Google Scholar 

  • Williams RO and C Hu. “Influence of water on the solubility of two steroid drugs in hydrofluoroalkane (HFA) propellants.” Drug Development and Industrial Pharmacy (2001) 27:71–79.

    Article  PubMed  CAS  Google Scholar 

  • Wood RE and MR Knowles. “Recent advances in aerosol therapy.” Journal of Aerosol Medicine (1994) 7:1–11.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GlaxoSmithKline, 881-895 Greenford Road, UB6 0HE, Greenford, Middlesex, UK

    John N. Pritchard

Authors
  1. John N. Pritchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Technology, Warsaw, Poland

    Leon Gradoń

  2. Faculty of Appplied Sciences, Delft University of Technology, Delft, The Netherlands

    Jan Marijnissen

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media Dordrecht

About this paper

Cite this paper

Pritchard, J.N. (2003). Recent Advances in Drug Delivery Via Pressured Metered-Dose Inhalers. In: Gradoń, L., Marijnissen, J. (eds) Optimization of Aerosol Drug Delivery. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-0267-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-0267-6_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6436-3

  • Online ISBN: 978-94-017-0267-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation